Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively

Gao, Su;Li, Zheng;Fu, Jian-Hong;Hu, Xiao-Hui;Xu, Yang;Jin, Zheng-Ming;Tang, Xiao-Wen;Han, Yue;Chen, Su-Ning;Sun, Ai-Ning;Wu, De-Pei;Qiu, Hui-Ying

  • Published : 2015.10.06


Background: We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype. Materials and Methods: From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis. All patients were treated with decitabine alone ($20mg/m^2$ daily for 5 days) or combination AAG chemotherapy (Acla 20mg qod*4d, Ara-C $10mg/m^2$ q12h*7d, G-CSF $300{\mu}g$ qd, the dose of G-CSF adjusted to the amount in blood routinely). Results: In 35 patients, 15 exhibited a complete response (CR), and 6 a partial response (PR), the overall response rate (CR+PR) being 60% (21 of 35). Median disease-free survival was 18 months and overall survival was 14 months. In the 15 MDS patients with a complex karyotype, the CR rate was 53.3% (8 of 15); in 20 AML patients with complex karyotype, the overall response rate was 65% (13 of 20). The response rate of decitabine alone (22 cases) was 56.5% (13 of 22), while in the combination chemotherapy group (13 cases), the effective rate was 61.5% (8 of 13)(P>0.05). There are 15 patients with chromosome 7 aberration, after treatment with decitabine, 7 CR, 3 PR, overall response rate was 66.7% (10 of 15). Of 18 patients with 3 to 5 kinds of chromosomal abnormalities, 66.7% demonstrated a response; of 17 with more than 5 chromosomal abnormalities, 52.9% had a response. In the total of 35 patients, with one course (23 patients) and ${\geq}$two courses (12 patients), the overall response rate was 40.9% and 92.3% (P<0.05). Grade III to IV hematological toxicity was observed in 27 cases (75%). Grade III to IV infections were clinically documented in 7 (20%). Grades I to II non-hematological toxicity were infections (18 patients), haematuria (2 patients), and bleeding (3 patients). With follow-up until September 2013, 7 patients were surviving, 18 had died and 10 were lost to follow-up. In the 6 cases who underwent allogeneic hematopoietic stem cell transplantation (HSCT) all were still relapse-free survivors. Conclusions: Decitabine alone or combination with AAG can improve outcome of AML/MDS with a complex karyotype, there being no significant difference decitabine in inducing remission rates in patients with different karyotype. Increasing the number of courses can improve efficiency. This approach with fewer treatment side effects in patients with a better tolerance should be employed in order to create an improved subsequent chance for HSCT.


Decitabine;complex karyotype;myelodysplastic syndrome;acute myeloid leukemia


  1. Byrd JC, Mrozek K, Dodge RK, et al (2002). Pretreatment cytogenetic abnormalities are predictic of induction success cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and leukemia Group B (GALGB 8461). Blood, 100, 4325-36.
  2. Cheson BD, Bennett JM, Kopecky KJ, et al (2003). Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol, 21, 4642-9.
  3. Cheson BD, Greenberg PL, Bennett JM, et al (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-25.
  4. Ghanem H, Cornelison AM, Garcia-Manero G, et al (2013). Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk, 13, 289-94.
  5. Jabbour E, Garcia-Manero G, Ravandi F, et al (2013). Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk, 13, 131-8.
  6. Jahns-Streubel G, Reuter C, Auf der Landwehr U, et al (1997). Activity of thymidine kinase and of polymerase a as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood, 90, 1968-76.
  7. Joeckel TE, Lubbert M (2012). Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Semin Hematol, 49, 330-41.
  8. Kantarjian H, Oki Y, Garcia-Manero G, et al (2007). Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 109, 52-7.
  9. Lowenberg B, van Putten W, Theobald M, et al (2003). Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med, 349, 743-52.
  10. Lubbert M, Suciu S, Baila L, et al (2011). Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European organization for research and treatment of cancer leukemia group and the German MDS Study Group. J Clin Oncol, 29, 1987-96.
  11. Ravandi F, Issa JP, Garcia-Manero G, et al (2009). Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer, 115, 5746-51.
  12. Shin DY, Sung Kang H, Kim GY, et al (2013). Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Biomed Pharmacother, 67, 305-11.
  13. Slovak ML, Kopecky KJ, Cassileth PA, et al (2000). Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 4075-83.
  14. Sole F, Espinet B, Sanz GF, et al (2000). Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Group Cooperative Espanolde Citogenetica Hematologica. Br J Haematol, 108, 346-56.
  15. Steensma DP, Baer MR, Slack JL, et a1 (2009). Multi-center study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for out patient treatment (ADOPT) tria1. J Clin Oncol, 27, 3842-48.
  16. Wawrzyniak E, Wierzbowska A, Kotkowska A, et al (2013). Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: Retrospective PALG study. Leuk Res, 37, 293-9.
  17. Yang XF, Sun AN, Yin J, et al (2012). Monosomal karyotypes among 1147 Chinese patients with acute myeloid leukemia: prevalence, features and prognostic impact. Asian Pac J Cancer Prev, 13, 5421-6.

Cited by

  1. Spectrum of the WHO Classification De Novo Myelodysplastic Syndrome: Experience from Southern Pakistan vol.17, pp.3, 2016,
  2. Adult Primary Myelodysplastic Syndrome: Experience from a Tertiary Care Center in Pakistan vol.17, pp.3, 2016,
  3. mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes vol.176, pp.4, 2016,
  4. Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone vol.143, pp.5, 2017,


Supported by : National Natural Scientific Foundation